{"entity":{"type":"insider","cik":"0001985496","url":"/insider/0001985496","json_url":"/insider/0001985496.json","name":"Ye Weiguo","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":8,"first":"2026-05-18","last":"2026-06-22","span_basis":"filed_date"},"name_variants":[{"name":"Ye Weiguo","source":"filing","n_filings":8,"first_seen":"2026-05-18","last_seen":"2026-06-22"}],"transactions":[{"id":6086249,"accession":"0001140361-26-025950","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001140361-26-025950","line_url":"/filing/0001140361-26-025950#line-6","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":6.35,"price_display":"6.35","price_state":"stated","total_value":19050.0,"total_display":"19,050.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-18","filed_date":"2026-06-22","scope":"insider"},{"id":6151786,"accession":"0001140361-26-025208","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-025208","line_url":"/filing/0001140361-26-025208#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2800.0,"shares_display":"2,800","price_per_share":6.17,"price_display":"6.17","price_state":"stated","total_value":17276.0,"total_display":"17,276.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-11","filed_date":"2026-06-15","scope":"insider"},{"id":6086244,"accession":"0001140361-26-025950","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-025950","line_url":"/filing/0001140361-26-025950#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":6.24,"price_display":"6.24","price_state":"stated","total_value":31200.0,"total_display":"31,200.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-10","filed_date":"2026-06-22","scope":"insider"},{"id":6071990,"accession":"0001140361-26-024929","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-024929","line_url":"/filing/0001140361-26-024929#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6418.0,"shares_display":"6,418","price_per_share":6.21,"price_display":"6.21","price_state":"stated","total_value":39855.78,"total_display":"39,855.78","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-10","filed_date":"2026-06-11","scope":"insider"},{"id":6086237,"accession":"0001140361-26-025950","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-025950","line_url":"/filing/0001140361-26-025950#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":6.15,"price_display":"6.15","price_state":"stated","total_value":18450.0,"total_display":"18,450.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-09","filed_date":"2026-06-22","scope":"insider"},{"id":6071986,"accession":"0001140361-26-024929","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-024929","line_url":"/filing/0001140361-26-024929#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14500.0,"shares_display":"14,500","price_per_share":6.14,"price_display":"6.14","price_state":"stated","total_value":89030.0,"total_display":"89,030.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-09","filed_date":"2026-06-11","scope":"insider"},{"id":5893298,"accession":"0001140361-26-024449","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-024449","line_url":"/filing/0001140361-26-024449#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15401.0,"shares_display":"15,401","price_per_share":6.4,"price_display":"6.40","price_state":"stated","total_value":98566.4,"total_display":"98,566.40","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-05","filed_date":"2026-06-08","scope":"insider"},{"id":5893294,"accession":"0001140361-26-024449","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-024449","line_url":"/filing/0001140361-26-024449#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19575.0,"shares_display":"19,575","price_per_share":6.13,"price_display":"6.13","price_state":"stated","total_value":119994.75,"total_display":"119,994.75","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-04","filed_date":"2026-06-08","scope":"insider"},{"id":5781809,"accession":"0001140361-26-022980","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-022980","line_url":"/filing/0001140361-26-022980#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":6.1001,"price_display":"6.10","price_state":"stated","total_value":24400.4,"total_display":"24,400.40","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-27","scope":"insider"},{"id":5781807,"accession":"0001140361-26-022980","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-022980","line_url":"/filing/0001140361-26-022980#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":6.08,"price_display":"6.08","price_state":"stated","total_value":21280.0,"total_display":"21,280.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-27","scope":"insider"},{"id":5869903,"accession":"0001140361-26-022642","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-022642","line_url":"/filing/0001140361-26-022642#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12820.0,"shares_display":"12,820","price_per_share":6.15,"price_display":"6.15","price_state":"stated","total_value":78843.0,"total_display":"78,843.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-21","filed_date":"2026-05-22","scope":"insider"},{"id":5869901,"accession":"0001140361-26-022642","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-022642","line_url":"/filing/0001140361-26-022642#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9400.0,"shares_display":"9,400","price_per_share":6.15,"price_display":"6.15","price_state":"stated","total_value":57810.0,"total_display":"57,810.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-20","filed_date":"2026-05-22","scope":"insider"},{"id":6035302,"accession":"0001140361-26-022235","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-022235","line_url":"/filing/0001140361-26-022235#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9120.0,"shares_display":"9,120","price_per_share":6.37,"price_display":"6.37","price_state":"stated","total_value":58094.4,"total_display":"58,094.40","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-19","filed_date":"2026-05-20","scope":"insider"},{"id":6035297,"accession":"0001140361-26-022235","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-022235","line_url":"/filing/0001140361-26-022235#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":6.62,"price_display":"6.62","price_state":"stated","total_value":1324.0,"total_display":"1,324.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-20","scope":"insider"},{"id":5748432,"accession":"0001140361-26-021889","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001140361-26-021889","line_url":"/filing/0001140361-26-021889#line-4","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13100.0,"shares_display":"13,100","price_per_share":6.65,"price_display":"6.65","price_state":"stated","total_value":87115.0,"total_display":"87,115.00","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-15","filed_date":"2026-05-18","scope":"insider"},{"id":5748429,"accession":"0001140361-26-021889","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-26-021889","line_url":"/filing/0001140361-26-021889#line-2","is_derivative":false,"issuer_cik":"0001124105","issuer_name":"GYRE THERAPEUTICS, INC.","issuer_ticker":"GYRE","issuer_name_source":null,"issuer_url":"/issuer/0001124105","owner_cik":"0001985496","owner_name":"Ye Weiguo","owner_url":"/insider/0001985496","role":"Officer (Chief Operating Officer)","officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15580.0,"shares_display":"15,580","price_per_share":6.91,"price_display":"6.91","price_state":"stated","total_value":107657.8,"total_display":"107,657.80","shares_owned_after":700000.0,"shares_owned_after_display":"700,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-14","filed_date":"2026-05-18","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":16,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001124105","name":"GYRE THERAPEUTICS, INC.","url":"/issuer/0001124105","role":"Officer (Chief Operating Officer)","n_filings":8,"first_seen":"2026-05-18","last_seen":"2026-06-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001985496","retrieved_at":"2026-08-21T19:49:50+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}